VRCA Stock Analysis: Buy, Sell, or Hold?
VRCA - Verrica Pharmaceuticals Inc. Common Stock
$4.82
-0.04 (-0.82%)
▼
5d:
-3.02%
30d:
-11.4%
90d:
-18.31%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When VRCA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: VRCA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: VRCA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: VRCA is currently trading at $4.82, which is considered oversold relative to its 30-day fair value range of $4.96 to $5.50.
Technical Outlook: Technically, VRCA is in a downtrend. Immediate support is located at $4.64, while resistance sits at $5.85.
Market Sentiment: VRCA scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.80 (+207.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VRCA is in a downtrend. Immediate support is located at $4.64, while resistance sits at $5.85.
Market Sentiment: VRCA scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.80 (+207.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.96 -
$5.50
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 207.1% below Wall St target ($14.80)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.96 -
$5.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.64
Resistance Level
$5.85
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.27
Wall Street Target
$14.80
(+207.1%)
Revenue Growth (YoY)
-53.9%
Profit Margin
-102.8%
Share & Embed Analysis
Last updated: August 23, 2026 9:48 PM ET
Data refreshes hourly during market hours. Next update: 10:48 PM
Data refreshes hourly during market hours. Next update: 10:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRCA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
